Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, has announced its national title sponsorship of the inaugural ZENPEP(R) CF Cycle for Life tour series, a new fundraising event of the Cystic Fibrosis Foundation. The announcement was made at the CF Foundation’s national headquarters, with Eurand donating $300,000 to support vital cystic fibrosis programs and research. Launching in the summer and fall of 2010, ZENPEP CF Cycle for Life is a series of one-day cycling tours to be held in 18 US cities, where thousands of cyclists will come together to raise money to help find a cure for cystic fibrosis.

“Eurand is proud to serve as national sponsor of the inaugural ZENPEP CF Cycle for Life series,” said Ruth Thieroff-Ekerdt, MD, Eurand’s Chief Medical Officer. “We’re pleased to support the Cystic Fibrosis Foundation in its efforts to advance life-saving medical research for CF and develop therapies that have the potential to add decades of life for those with this devastating disease.”

Eurand manufactures and markets ZENPEP(R) (pancrelipase) Delayed-Release Capsules, an FDA-approved pancreatic enzyme product (PEP) indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions. This condition affects approximately 90% of patients with CF.

“We are thrilled by Eurand Pharmaceuticals’ commitment to help support the Cystic Fibrosis Foundation’s mission and the CF Cycle for Life series,” said Robert J Beall, PhD, president and CEO of the Cystic Fibrosis Foundation. “With Eurand’s support of this event, the CF Foundation looks forward to continuing the fight against cystic fibrosis, helping patients live longer, healthier lives.”

ZENPEP was approved by the FDA on 27 August 2009 and launched in November. For patients, families and caregivers affected by the FDA’s 28 April 2010 deadline, which the FDA indicated as a Stop Distribution date for unapproved PEPs, ZENPEP(R) is available in pharmacies nationwide. “We hope the ZENPEP CF Cycle for Life series also will raise awareness of the need for patients with EPI to use approved pancreatic enzyme therapies, which meet the FDA’s current safety, effectiveness and product-quality standards,” Thieroff-Ekerdt said.

The 2010 ZENPEP CF Cycle for Life series begins on June 26 in San Francisco, Calif. Other cities include Atlanta, Baton Rouge, La, Boston, Charleston, SC, Denver, Dayton, Ohio, Grand Rapids, Mich., Hartford, Conn, Jacksonville, Fla, Portland, Ore., Malvern, Pa, Peoria, Ill, Phoenix, San Diego, Seattle, Tampa, and Tyler, Texas.